A Randomised, DB, PC Study to Determine the PK, Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of AZD7295 in Otherwise Healthy Male and Female Hepatitis C Carriers With Compensated Liver Disease.

Trial Profile

A Randomised, DB, PC Study to Determine the PK, Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of AZD7295 in Otherwise Healthy Male and Female Hepatitis C Carriers With Compensated Liver Disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Apr 2010

At a glance

  • Drugs AZD 7295 (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors Arrow Therapeutics
  • Most Recent Events

    • 02 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Apr 2010 Actual patient number (31) added as reported by ClinicalTrials.gov.
    • 17 Feb 2010 Planned end date changed from 1 Nov 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top